Stichting Hemato-oncologie Voor Volwassenen Nederland

This study is testing whether a drug called tislelizumab, when combined with standard chemotherapy, works as well as the usual intensive treatment for Hodgkin lymphoma that has returned or didn't respond to first-line therapy. The trial involves 75 adults aged 18-70. The goal is …

This study tests whether adding the immunotherapy drug atezolizumab after standard chemotherapy can help prevent cancer from returning in patients with high-risk diffuse large B-cell lymphoma. The trial enrolled 109 adults who had responded well to initial treatment but remain at…